ESMO 2025 | Occupational exposure risks from chemotherapy and emerging immunotherapies in oncology
Karen Campbell, PhD, Edinburgh Napier University, Edinburgh, UK, discusses occupational exposure risks associated with cytotoxic chemotherapy and emerging cancer therapies. She explains that while chemotherapy-related contamination is well-documented and detectable, healthcare workers may also face unrecognized risks from newer agents such as immunotherapies. Dr Campbell emphasizes the need for further research to understand and monitor potential health effects from these treatments, highlighting the importance of expanding safety protocols beyond traditional cytotoxic drugs to ensure comprehensive protection for oncology staff. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
